Economic Observer Network reporter Zhang Yingdong news network reported on June 5 that anonymous alumni donated 300 million yuan to Southeast University, becoming the highest single donation received by Southeast University so far.
The anonymous donor said that Southeast University is the starting point for him to pursue his dreams, and this donation is to help southeast university medical construction and support southeast university to establish a medical science and technology and engineering research institute (college).
The Institute of Medical Science and Technology and Engineering (College) of Southeast University here is the news of the strategic cooperation agreement signed by Southeast University and Qiangxin Technology, which was also released on June 5, the anonymous alumni donation.
In the UTokyo press release about the strategic cooperation, it is mentioned that Li Jiaqiang, chairman of Qiangxin Technology Group, is a 1980 alumnus of the School of Public Health/School of Medicine of Southeast University (formerly Nanjing Railway Medical College).
Lilac Garden's public account "Lilac Medical Student" said that the anonymous donor of 300 million yuan was Li Jiaqiang, chairman of Qiangxin Technology Group.
On June 9, the Economic Observer Network called the Southeast University Development Committee to inquire about the donor and the progress of the donation, and the staff said that it was inconvenient to disclose the details. Subsequently, Beijing Qiangxin Technology Co., Ltd., which is controlled by Li Jiaqiang, said it would not accept an interview on the issue.
Distinguished alumni with more than 20 titles
Li Jiaqiang has many titles. In the introduction of him by the Dongda News Network, there are more than 20 titles.
He was the first Chinese to receive a Doctor of Medicine degree from Harvard University and to complete his Residency and Specialist Training at Harvard University. He is currently an Honorary Distinguished Fellow of the Royal College of Physicians, an Academician of the National Academy of Inventors, the first batch of specially invited directly elected Academicians of the American Academy of Internal Medicine, and a member of the Overseas Expert Advisory Committee of the State Council. He is currently the chairman of Qiangxin Technology Group and the president of Qiangxin International Research Institute of Technology; Director of the Highest Management Board of Harvard University BIDMC Hospital, Director of Ekman Molecular Targeted Therapy Center, Expert in Gastrointestinal Diseases and Cancer in Internal Medicine, Postdoctoral Supervisor, Member of the Board of Fellows of Harvard Medical School, Executive Director of the Chinese Invention Association and the first expert of the Academician Expert Committee, Director of the Chinese Overseas Friendship Association of the United Front Work Department of the Central Committee, etc.
The Economic Observer Network reporter checked the relevant information and found that Li Jiaqiang's so-called first Chinese who obtained a doctorate in medicine from Harvard University and was selected to complete the training of residents and expert physicians at Harvard University is quite puzzling. He did receive a M.D. from Harvard University as a Chinese, but not the first, the first Chinese to receive a M.D. from Harvard University, liu Ruiheng, the first Chinese dean of Union Hospital, was obtained in 1913. Li graduated from Harvard Medical School in 1998 and went on to complete residency and specialist training at Harvard Medical School, which is an essential condition for becoming a doctor.
The Royal College of Physicians of London, mentioned in one of the many titles, can also be translated as the Royal College of Physicians. According to a member of the society, in the United Kingdom, a fellow of the Royal College of Physicians of London (FRCP) can be a member of the society , and honorary and Distinguished Fellows are honorary physicians who have not been awarded an examination and cannot practice formally.
The National Academy of Inventors, founded in 2010, is a nonprofit organization founded by Paul R. Sanberg, distinguished professor at the University of South Florida School of Medicine, that embraces inventors who have patents and are actively promoting the transformation of research results. According to the organization's official website, there are currently 1567 academicians (Fellows), and Li Jiaqiang is one of them, who became an academician of the organization in 2014 along with 168 other inventors.
The American College of Physicians, or American College of Physicians. Similar to the Royal College of Physicians, it provides knowledge sharing, industry standard setting and other services for physicians, and currently has 160,000 members (members), making it the largest medical professional association in the world.
It claims to design a new generation of covid-19 mRNA vaccines
In 2006, Li Jiaqiang founded Qiangxin Technology Holdings and established Boston Biotechnology Company (BBI).
In 2012, Boston Biotechnology was favored by Japan's Sumitomo Pharmaceutical Group (DSP) for two drugs under development, BBI608 and BBI503, and DSP planned to acquire BBI for $2.63 billion, of which $200 million was used to acquire shares of BBI shareholders, $540 million was funded for drug research and development, and the remaining $1.89 billion needed to be paid after the two drugs were listed to achieve profits.
In June 2016, BBI608 was approved by the FDA for the treatment of gastroesophageal junction (GEJ) cancer, and in November of the same year, the FDA approved its new indication: pancreatic cancer. However, the approval information of BBI503 has not yet been queried.
In March 2017, Li Jiaqiang resigned as CEO of Boston Biotech and is no longer the head of the global oncology business at Sumitomo Pharmaceutical Group in Japan.
In China, since 2011, Li Jiaqiang has founded Beijing Qiangxin Biological, Nanjing Qiangxin, Nanjing Byoji, Hangzhou Qiangxin, Chengdu Qiangxin and other enterprises. On June 6, 2022, Beijing Qiangxin announced on its official website that it has successfully designed a new generation of mRNA vaccines against mutant strains such as Ami Kerong and Delta, and announced that it plans to complete clinical trials at the end of 2022 or the first half of 2023 and achieve large-scale production.
He was the largest shareholder of Kexing Biologics
Li Jiaqiang was also known as the largest shareholder of Kexing Biotech (SVA.NASDAQ). According to relevant documents from the US Securities and Exchange Commission, in May 2018, Li Jiaqiang's actual equity in the common stock of Kexingsheng Bio once reached 32.6%.
Between May 2013 and April 2016, 1Globe CapitalLLC (hereinafter referred to as 1Globe), which Li Jiaqiang actually controlled, and Li Jiaqiang's personal holdings of Coxing Biocorp increased from 6.19% to 22.5%.
But since then, from the end of April 2016 to December 2017, Li Jiaqiang has increased his holdings of 8.49% of his common stock in the name of others. Become the de facto largest shareholder. However, none of these increases were disclosed as required, and as a result, they were punished by the SEC in May 2020, with Li Jiaqiang and 1Globe fined $90,000 and $200,000, respectively.
At the 2017 Annual General Meeting of Shareholders of Kexing Biotech held in February 2018, Li Jiaqiang voted against the re-election of four directors, including chairman Yin Weidong, proposed a new board candidate list, and successfully obtained a majority of votes at the shareholders' meeting. However, Coxing Bio believes that the candidate list is not legal. 1Globe filed a lawsuit against this without being upheld by the district court.
Since February 22, 2019, Coxing Bio has suspended trading and issued an announcement to launch the "Poison Pill Plan", saying that due to the triggering of the rights plan by some shareholders, nearly 40% of the common shares and a large number of preferred shares will be issued to common shareholders who have not triggered the rights plan, which directly leads to the dilution of the shares held by Li Jiaqiang, so as to no longer occupy the position of the largest shareholder.